QTRXNasdaqLaboratory Analytical InstrumentsUS GAAP · USD

Quanterix Corp

Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples. Its portfolio includes Simoa-based instruments, consumables, and the Accelerator Laboratory service platform, with customers served through direct sales and distribution channels in North America, Europe, and other international markets.

Kysy yhtiöstä
Liikevaihto139milj. USD
+1,1 %v/v
Liikevoitto (EBIT)−126milj. USD
−138,6 %v/v
EBIT-marginaali−90,4%
−52,1 %-yks.v/v
Nettotulos−107milj. USD
−178,1 %v/v
Vapaa kassavirta−79,8milj. USD
−107,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−1000100200milj. USD2020: 86 milj. USD2020: EBIT −32 milj. USD20202021: 111 milj. USD2021: EBIT −59 milj. USD20212022: 106 milj. USD2022: EBIT −104 milj. USD20222023: 122 milj. USD2023: EBIT −46 milj. USD20232024: 137 milj. USD2024: EBIT −53 milj. USD20242025: 139 milj. USD2025: EBIT −126 milj. USD2025139−126
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Quanterix Corp

Liiketoiminta

Osuus liikevaihdosta
Instruments20 %

Analytical instruments used for proteomics, biomarker detection, and spatial biology workflows.

Consumables and assay kits55 %

Reagents, bead-based consumables, and assay kits used with installed instruments.

Services25 %

Accelerator Laboratory and other research or collaboration services.

Tuotteet

Raportoitu · osuus liikevaihdosta
54,1%18,7%12,9%FY2025100 %
  • Consumable and Other Products54,1 %
  • Research Services18,7 %
  • Instrument Products12,9 %
  • Service Type Warranties8,0 %
  • Other Services5,1 %
  • Muut1,3 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Quanterix sells primarily to life science researchers, pharmaceutical and biotech companies, and clinical research organizations that need highly sensitive protein measurement tools. It also serves academic and government research customers, and increasingly supports diagnostic-oriented applications through collaborations and test commercialization efforts.

Pharmaceutical and biotech R&D

Buys instruments, consumables, and services for biomarker discovery and clinical research.

Academic and government research

Uses Simoa systems and assays for basic and translational research applications.

Clinical research organizations

Outsources specialized testing and laboratory services for sponsored studies.

Diagnostic and clinical partners

Evaluates assays and platforms for future diagnostic or LDT applications.

Strategia

Quanterix is focused on expanding its installed base, launching new instruments and tests, and extending its platform into diagnostics and spatial biology. It also emphasizes global distribution, customer support, and collaborations with key opinion leaders to strengthen adoption and defend its position in sensitive biomarker measurement.

Commercialize new instruments and assaysLyhyt aikaväli

New products are central to replacing aging systems and sustaining platform relevance.

Expand diagnostics and clinical applicationsKeskipitkä aikaväli

Diagnostic use cases can broaden the addressable market beyond research customers.

Build international distribution coverageKeskipitkä aikaväli

International markets are a meaningful source of growth and require local support.

Strengthen customer retention and installed-base utilizationLyhyt aikaväli

Consumables and service revenue depend on active instrument usage and repeat demand.

Maantiede

Quanterix operates with a global customer base, with a substantial share of revenue generated outside North America. The company maintains sales, support, and marketing personnel primarily in North America and Europe, and it is building distribution and support capabilities in China and broader APAC markets.

Riskit

Quanterix faces competition from larger life science instrument companies and smaller specialists across proteomics, spatial biology, and diagnostics. Its results are also exposed to customer concentration, international execution risk, product development delays, and accounting/control issues tied to acquisitions and complex estimates.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Acquisition integration and internal control risk1Competitive pressure from larger and specialized rivals2Product development and launch delays3Customer concentration4International execution and compliance risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Acquisition integration and internal control riskVaikutus: KorkeaTodennäköisyys: Korkea

    Integrating acquired businesses and remediating control weaknesses can create reporting and execution risk.

    Kohdistuu: Akoya integration and financial reporting

  2. Competitive pressure from larger and specialized rivalsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company competes with firms such as Bio-Techne, 10x Genomics, Bruker, and others across multiple platforms.

    KohdistuuProteomicsSpatial biologyDiagnostics
  3. Product development and launch delaysVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Technical challenges or supply chain issues could slow commercialization of next-generation instruments.

    Kohdistuu: instrument refresh and new assays

  4. Customer concentrationVaikutus: KorkeaTodennäköisyys: Matala

    A meaningful portion of revenue comes from a limited number of large customers, increasing volatility if one reduces spend.

    Kohdistuu: top customers and major pharma accounts

  5. International execution and compliance riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Growth outside North America depends on distributors, foreign regulations, and anti-bribery compliance.

    KohdistuuEuropeChinaAPAC
Kysy Clarifolta: Quanterix Corp

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition across multiple revenue streams

Instruments, consumables, services, and licenses may recognize revenue at different times, affecting comparability.

Vaikutus: Quarterly mix and timing can shift reported revenue materially

Acquisition accounting for Akoya and other deals

Fair value allocation creates goodwill, intangibles, and off-market contract adjustments.

Vaikutus: Can affect revenue, amortization, and impairment risk

Goodwill and intangible asset impairment

Acquired assets must be tested if performance or market conditions weaken.

Vaikutus: Potential non-cash charges if expected benefits do not materialize

Contingent consideration and fair value estimates

Acquisition-related liabilities depend on valuation assumptions and future outcomes.

Vaikutus: Can create earnings volatility through remeasurement

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Quantum-Si Inc

QSI · Measuring & Controlling Devices, NEC

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

Standard BioTools Inc

LAB · Pharmaceutical Preparations

Qiagen N.V

QGEN · Biological Products, (No Diagnostic Substances)

Biomerica, Inc

BMRA · In Vitro & In Vivo Diagnostic Substances

QuidelOrtho Corp

QDEL · In Vitro & In Vivo Diagnostic Substances

Päivitetty: 24.9.2026

Quanterix Corp (QTRX) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo